Flow cytometry for diagnosis and assessment of prognosis in patients with myelodysplastic syndromes.
The Myelodysplastic Syndrome (MDS) comprises a spectrum of hematopoietic stem cell disorders. Identification of additional parameters that might distinguish different risk groups or entities would be useful. Flow cytometric studies have begun to characterize individual or composite immunophenotypic abnormalities as well as light scatter properties that may be helpful for diagnosis and of prognostic value for the natural course of the disease and for outcome after therapy. Here we review the current state of the art of the use of flow cytometry in patients with MDS.
Benesch
Martin
M
Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Deeg
H Joachim
HJ
Wells
Denise
D
Loken
Michael
M
D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D016130:Immunophenotyping / Q000379:methods; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000453:epidemiology / Q000276:immunology / Q000473:pathology*; D018570:Risk Assessment